China's approved slow hepatitis B drug, Wei lide ® officially listed

With the increase of hepatitis B vaccination coverage, the number of hepatitis B infection in China has decreased significantlyHowever, the status quo of diagnosis and treatment remains bleak1/3 patients with chronic hepatitis B do not know that there is an effective anti-HBVdrug(http://, more than half of patients with chronic hepatitis B have never carried out standardized antiviral treatment, more than 60% of patients with chronic hepatitis B did not meet the standard before stopping the drugGilead Scientific(http://(NASDAQ: GILD) announced that the approved slow hepatitis BDrug(http:// approved in China on November 8® the official listing of the(http://(NASDAQ: GILD)about the living ® of The Wellid (
Vereed ® (TAF, 25mg of propofavir) can be used to treat chronic hepatitis B (HBV) in adults and adolescents (over 12 years of age and weighing at least 35 kg)Over the past decade, the ® has been the only (http:// new
hepatitis B drug approved for the of the FDA (http:// ) From now on, patients with chronic hepatitis B in China will be able to simultaneously obtain innovative drugs from around the world the day of the conference, Taikang care for liver slow hepatitis B patients full course of disease coverage plan project released at the same time Gilead Sciences and Taikang Insurance Group will work together to provide more effective and safer treatment and more integrated health management and risk protection for patients in China with the common goal of improving the benefits of the health (http://